Sorrento In-Licenses COVID-19 Targeted MPro Inhibitors

Sorrento Therapeutics Inc SRNE has entered into an option agreement with The Texas A&M University System for exclusive rights to highly potent main protease (MPro) inhibitors against SARS-CoV-2.
This latest agreement bolsters Sorrento's portfolio of preclinical and clinical therapeutic candidates targeting COVID-19.
Under the agreement terms, Sorrento has an exclusive option to license patents covering the MPro inhibitor drug candidates exclusively.
The MPro inhibitors have demonstrated strong cellular antiviral potency against SARS-CoV-2 in preclinical studies.
Several MPro inhibitors were identified that exhibited antiviral effects against diverse SARS-CoV-2 variants.
Sorrento may exercise its right to enter into a worldwide exclusive license agreement at any time during the option period.
Price Action: SRNE shares are up 0.32% at $8.96 during the market session on the last check Tuesday.